Salirasib
Information
- Drug Name
- Salirasib
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| lung adenocarcinoma | KRAS MUTATION KRAS MUTATION | B |
Predictive
|
Does Not Support
|
Sensitivity/Response | Somatic | 3 | 21847063 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| In a study of 30 lung adenocarcinoma patients with... | KRAS | KRAS MUTATION KRAS MUTATION | Sensitivity | false | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00531401 | Completed | Phase 2 | Study of Salirasib to Treat Non-Small Cell Lung Cancer | September 2007 | November 2009 |
- Target (Drug list of Screening Committee of Anticancer Drugs)
- Farnesyltransferase (FTPase)/ Ras signaling
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- farnesyl thiosalicylic acid
- Synonym (Drug list of Screening Committee of Anticancer Drugs)
- ONO-7056